Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Capital Expenditures (2024 - 2025)

Prelude Therapeutics (PRLD) has disclosed Capital Expenditures for 2 consecutive years, with $20000.0 as the latest value for Q2 2025.

  • Quarterly Capital Expenditures fell 94.43% to $20000.0 in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $67000.0 through Dec 2025, up 570.0% year-over-year, with the annual reading at $67000.0 for FY2025, 570.0% up from the prior year.
  • Capital Expenditures hit $20000.0 in Q2 2025 for Prelude Therapeutics, down from $47000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $359000.0 in Q2 2024 to a low of -$701000.0 in Q4 2024.